ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)

Condition studied

Advanced Renal Cell Carcinoma

Investigational medicinal product(s)

Eligibility

Primary endpoint

Phase 1: The main goal of phase 1 will check and count for how many people have side-effects or serious side-effects from the medicine, if anyone must stop taking it because of these side-effects , and if any side-effects cause death., Phase 2: The main goal of phase 2 will be to check and count how many people's kidney cancer gets much smaller or completely goes away with the treatment (OR (Objective Response) (confirmed CR (complete response) or PR (partial response)).

Endpoint detail

Count how many people have side-effects or serious side-effects from the medicines, including those who stop treatment or die because of them (safety)., See how long people live without the cancer getting worse, and how long the cancer stays smaller or goes away (progression delay (PFS, Progression-Free Survival and duration (DOR, Duration of Response).